A Phase 1/2 Study of Durvalumab(MEDI4736) and tremelimumab in Chinese Patients with Advanced Malignancies

Trial Identifier:	D419AC00006
Sponsor:	AstraZeneca
NCTID::	NCT02978482
Start Date:	December 2016
Primary Completion Date:	January 2018
Study Completion Date:	November 2020
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	Chinese Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Changchun, China, 130012

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.